首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
admin
2017-03-15
47
问题
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought grew worse. According to newly released statistics from the Food and Drug Administration (FDA), it approved only 20 new drugs, down from 36 in 2004. Only once in last 10 years has the number of newly approved drugs been lower than last year’s figure.
The dry spell in 2005 came even as spending on research by the industry reached a new high, passing $38 billion. And in a rarity, several major companies failed to win approval for a new drug invented in their own labs, including Pfizer, Eli Lilly and Johnson & Johnson.
The decline in drug development came as scientists in and outside the companies were making great strides in genomics and other sorts of basic research into the way diseases develop, opening many potential new targets for treatment. Yet such progress in the laboratory has not translated so far into many new drugs on the market.
Some analysts say that the drug industry is in a cyclical trough, and that the number of new drugs—not just new applications for drugs already on the market—will start rising within a few years as research investments begin to pay off. But the FDA and the companies seem to agree that the process for testing and developing new drugs needs improvement.
"Our concern is that the development process itself is not keeping up at a fast enough pace to match the progress on the discovery end," said Dr. Scott Gottlieb, the agency’s deputy commissioner for medical and scientific affairs.
The FDA is looking for ways to speed the approval of new treatments—like approving drugs based on "surrogate endpoints," whether, for example, a cancer drug causes tumors to shrink instead of whether it prolongs the life of patients. It was on such a basis that the FDA last month approved Nexavar, a Bayer drug for treating kidney cancer.
But like finding new treatments, diagnosing the problem of drug development is easier than figuring out a solution. Even as the FDA looks for ways to speed the testing of new treatments, members of Congress and some consumer groups are calling for even more testing before drugs are approved.
The low output from research last year was even worse than the top-line figures might indicate. In 2004, important cancer treatments including Avastin, by Genentech, and Tarceva, through a partnership of Genentech and OSI Pharmaceuticals, were among the therapies that regulators allowed onto the market. The drugs that were approved were mostly for rare diseases like chronic iron overload, a condition for which the Novartis medicine Exjade received clearance.
In the meantime, the agency delayed approval of prominent new treatments like Pargluva, a diabetes drug from Bristol-Myers Squibb and Merck, and Exubera, a form of inhaled insulin from Pfizer.
The paucity of new products is a big reason that the stock prices of large drug makers have tended to fare poorly in recent years. Shares of Pfizer, the industry leader, for example, reached a peak of $49 in July 2000 and have trended downward since, closing yesterday at $24.44.
The drought in new drugs has led some industry executives to complain that the FDA is denying approval to good new treatments because of the criticism the agency has faced from lawmakers over Vioxx. Merck stopped selling its arthritis painkiller Vioxx in 2004 after a clinical trial showed that it increased the risks of heart attacks and strokes in patients taking it for 18 months or longer. Some other studies found heart attack risks as early as 2000, and the FDA has been criticized for not forcing Merck to withdraw the drug earlier or to warn doctors prominently of such risks.
Researching and developing a drug is a long and arduous process. Genentech’s work leading to Avastin, for example, began in 1989—15 years before the drug’s approval. Scientists first identify the cellular process of disease within the body. They may search for proteins that cancerous tumors release in order to spread, or receptors on the surface of a cell that become the targets of viruses.
The drug company then searches for chemical compounds or proteins that are able to interact with the targets the scientists have found—without damaging cells in other parts of the body. If a treatment appears to have therapeutic effects in test-tube and animal trials, the companies then move on to Phase I human testing, when a handful of healthy volunteers are given the therapy to make sure that it is safe enough for wider testing. In Phase II testing, the drug is tried on a few dozen to a few hundred patients for safety and effectiveness.
Finally, in Phase III development, the drug is tested in large-scale trials with as many as several thousand patients to demonstrate its effectiveness and to search for rarer side effects.
If the treatment is shown to be unsafe or ineffective at any stage, it fails development and is put aside.
According to a report in December from Merrill Lynch, the number of potential new drugs in Phase I and II testing has nearly doubled in the last decade, to 1,971 in 2004 from 1,010 in 1995. But that has not translated into success in Phase III development; the number of drugs in Phase III has been flat at fewer than 400.
"R&D statistics over the past decade have been disappointing," Merrill’s analysts wrote in their report. Still, the analysts predicted that companies would continue to increase research spending and expand their pipelines of early-stage drugs.
According to the author, the possible reasons for the dry spell of pharmaceutical companies lie in all the following EXCEPT (that)______.
选项
A、the paucity of investment companies made in research
B、the drug industry had trended downward and currently reached its low point
C、the development process did not match the pace of the related researches
D、FDA postponed the approval of prominent new medications in 2004
答案
A
解析
转载请注明原文地址:https://kaotiyun.com/show/FCSO777K
本试题收录于:
NAETI高级口译笔试题库外语翻译证书(NAETI)分类
0
NAETI高级口译笔试
外语翻译证书(NAETI)
相关试题推荐
Wheneverwehearofanaturaldisaster,wefeelsympathetictothepeopletobeaffected.
Although"namingrights"haveproliferatedinAmericanhighereducationforthepastseveraldecades,thephenomenonhasrecentl
TherearebothgreatsimilaritiesandconsiderablediversityintheecosystemsthatevolvedontheislandsofOceaniainandaro
TherearebothgreatsimilaritiesandconsiderablediversityintheecosystemsthatevolvedontheislandsofOceaniainandaro
Everyautumn,retailershirelargenumbersofseasonalworkerstohandletherushofholidaybusiness.Then,afterthenewyear
1986年全国人大常委会副委员长班禅喇嘛在西康地区大法会上教诲信徒们,要爱惜民族团结,维护祖国统一。在中国,公民的信仰自由受到法律保护。目前全西藏在寺僧尼约有14,000多人,另有800位宗教界人士在各级人大、政协、佛教协会和政府部门中工作。
SeventeenyearsafterthefalloftheBerlinwall,areunifiedGermanywillthrowopenitsdoorstotheworld.Germany2006will
下面你将听到外国媒体有关中国能源形势的一段讲话。TightelectricitysupplyisconstrainingChina’seconomicgrowth—asituationlikelytopersistfo
Iwanttodiscusssomeideasabouthowwemanageunderground【B1】______.Ifweonlytakeasmuchoutascomesin,we’renotgoing
随机试题
使用塞尺时,根据测量需要可用一片或数片重叠在一起。塞尺实际上也是一种( )量规。
与单相奥氏体组织相比,()双相组织不锈钢的CO2气体保护焊的焊缝,具有较高的抗热裂能力。
答问的技巧有()
函数f(x)=在x=0点【】
下列不属于货币市场构成的是()。
2004年11月30日,北京市发展和改革委员会在京召开“关于调整世界文化遗产游览参观点门票价格听证会”后,北京故宫、天坛、颐和园、八达岭长城、定陵、长陵等景点门票纷纷涨价。随后全国不少景点跟着涨价,另一些景点也在酝酿涨价。然而面对2005年“五一”黄金周的
三严三实是习近平总书记对全党提出的具体要求,三严三实虽然是对全党的普遍要求,但是针对不同岗位职务具体落实。比如严以用权,对于行政审批岗位的党员干部和对于惠民服务的党员干部是不同的,主要体现的哲学原理是()。
新中国在对资本主义工商业的社会主义改造过程中,在利润分配上采取的政策:是
若α,β,γ是单位向量且满足α+β+γ=0,求以α,β为边的平行四边形的面积.
在考生文件夹下,打开文档WORDl.docx,按照要求完成下列操作并以该文件名(WORDl.docx)保存文档。【文档开始】新型硬盘借口——串行ATA及UltraATAl33随着硬盘容量和速度的飞速增加,硬盘借口也经历了很多次革命性的改变,从
最新回复
(
0
)